Genocea Biosciences, Inc. (NASDAQ:GNCA)‘s stock had its “overweight” rating reiterated by analysts at Piper Jaffray Companies in a report issued on Thursday, The Fly reports. They presently have a $5.00 price objective on the biotechnology company’s stock. Piper Jaffray Companies’ price objective would indicate a potential upside of 331.03% from the company’s previous close.

GNCA has been the subject of several other reports. Zacks Investment Research raised Genocea Biosciences from a “hold” rating to a “buy” rating and set a $1.75 price objective for the company in a research note on Monday, October 16th. ValuEngine lowered Genocea Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Stifel Nicolaus lowered Genocea Biosciences from a “buy” rating to a “hold” rating and lowered their price objective for the company from $15.00 to $2.50 in a research note on Monday, September 25th. Cowen and Company reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Genocea Biosciences in a research note on Tuesday, September 26th. Finally, Needham & Company LLC downgraded Genocea Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, September 26th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. Genocea Biosciences currently has an average rating of “Buy” and an average target price of $7.62.

Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.08).

TRADEMARK VIOLATION WARNING: This article was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/11/02/genocea-biosciences-gnca-overweight-rating-reiterated-at-piper-jaffray-companies.html.

Several hedge funds and other institutional investors have recently modified their holdings of GNCA. Ameriprise Financial Inc. raised its holdings in shares of Genocea Biosciences by 34.1% in the first quarter. Ameriprise Financial Inc. now owns 19,933 shares of the biotechnology company’s stock worth $121,000 after buying an additional 5,068 shares during the period. JPMorgan Chase & Co. purchased a new stake in shares of Genocea Biosciences in the first quarter worth approximately $217,000. FMR LLC raised its holdings in shares of Genocea Biosciences by 0.4% in the first quarter. FMR LLC now owns 4,274,804 shares of the biotechnology company’s stock worth $26,033,000 after buying an additional 18,574 shares during the period. Geode Capital Management LLC raised its holdings in shares of Genocea Biosciences by 4.7% in the first quarter. Geode Capital Management LLC now owns 148,370 shares of the biotechnology company’s stock worth $903,000 after buying an additional 6,708 shares during the period. Finally, Schwab Charles Investment Management Inc. purchased a new stake in shares of Genocea Biosciences in the second quarter worth approximately $257,000. Hedge funds and other institutional investors own 57.39% of the company’s stock.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

The Fly

Analyst Recommendations for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.